TTR and amyloidosis: Tafamidis and newer transthyretin stabilizers have redefined the prognosis of transthyretin amyloidosis, myosin inhibitors represent a breakthrough in hypertrophic cardiomyopathy, and structured surveillance has been recognized as essential in Takotsubo syndrome.